Loading...
Liraglutide (Victoza) is a glucagon-like peptide-1 analogue approved at 1.2–1.8 mg doses for treating patients with type 2 diabetes. Because it promotes weight loss, liraglutide at a higher dose (3.0 mg; branded as Saxenda) has been approved for weight management in nondiabetic and diabetic patients; however, high rates of gastrointestinal side effects have occurred in patients taking liraglutide at this higher dose (NEJM JW Gen Men Aug 1 2015 and N Engl J Med 2015; 373:11). In this industry-supported, randomized trial, 846 overweight or obese adults (mean body-mass index, 37 kg/m2; mean body weight, ≈106 kg) with type 2 diabetes received once-daily subcutaneous liraglutide (3.0 mg or 1.8 mg) or placebo for 56 weeks. All participants were b…